Logo image of TOI

ONCOLOGY INSTITUTE INC/THE (TOI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TOI - US68236X1000 - Common Stock

4.18 USD
-0.13 (-3.02%)
Last: 1/9/2026, 8:00:01 PM
4.19 USD
+0.01 (+0.24%)
After Hours: 1/9/2026, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TOI. TOI was compared to 101 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of TOI have multiple concerns. TOI is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TOI had negative earnings in the past year.
In the past year TOI has reported a negative cash flow from operations.
TOI had negative earnings in 4 of the past 5 years.
In the past 5 years TOI reported 4 times negative operating cash flow.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

TOI's Return On Assets of -33.41% is on the low side compared to the rest of the industry. TOI is outperformed by 85.15% of its industry peers.
Industry RankSector Rank
ROA -33.41%
ROE N/A
ROIC N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

TOI's Gross Margin of 14.82% is on the low side compared to the rest of the industry. TOI is outperformed by 64.36% of its industry peers.
In the last couple of years the Gross Margin of TOI has declined.
TOI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TOI has been increased compared to 1 year ago.
TOI has more shares outstanding than it did 5 years ago.
TOI has a worse debt/assets ratio than last year.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

TOI has an Altman-Z score of 1.46. This is a bad value and indicates that TOI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.46, TOI is not doing good in the industry: 65.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACCN/A
WACC8.75%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TOI has a Current Ratio of 1.68. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TOI (1.68) is better than 66.34% of its industry peers.
TOI has a Quick Ratio of 1.39. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
TOI has a Quick ratio (1.39) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.39
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.56% over the past year.
Looking at the last year, TOI shows a very strong growth in Revenue. The Revenue has grown by 21.67%.
TOI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.41% yearly.
EPS 1Y (TTM)16.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)21.67%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%36.7%

3.2 Future

TOI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.78% yearly.
TOI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.17% yearly.
EPS Next Y-36.9%
EPS Next 2Y12.33%
EPS Next 3Y20.78%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y22.12%
Revenue Next 3Y21.17%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TOI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as TOI's earnings are expected to grow with 20.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.33%
EPS Next 3Y20.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TOI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (1/9/2026, 8:00:01 PM)

After market: 4.19 +0.01 (+0.24%)

4.18

-0.13 (-3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners40.02%
Inst Owner Change0%
Ins Owners3.63%
Ins Owner Change-58.86%
Market Cap411.23M
Revenue(TTM)461.04M
Net Income(TTM)-54.66M
Analysts82.5
Price Target6.63 (58.61%)
Short Float %8.32%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.28%
Min EPS beat(2)-22.31%
Max EPS beat(2)-14.24%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.88%
Min Revenue beat(2)3.5%
Max Revenue beat(2)10.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.14%
EPS NQ rev (1m)-17.39%
EPS NQ rev (3m)10%
EPS NY rev (1m)-3.29%
EPS NY rev (3m)-5.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS4.69
BVpS-0.12
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.82%
FCFM N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
F-Score4
Asset Turnover2.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.49%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.68
Quick Ratio 1.39
Altman-Z 1.46
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)87.81%
Cap/Depr(5y)78.43%
Cap/Sales(3y)1.52%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-36.9%
EPS Next 2Y12.33%
EPS Next 3Y20.78%
EPS Next 5YN/A
Revenue 1Y (TTM)21.67%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%36.7%
Revenue Next Year20.72%
Revenue Next 2Y22.12%
Revenue Next 3Y21.17%
Revenue Next 5YN/A
EBIT growth 1Y35.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.83%
EBIT Next 3Y44.04%
EBIT Next 5YN/A
FCF growth 1Y47.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.09%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLOGY INSTITUTE INC/THE / TOI FAQ

Can you provide the ChartMill fundamental rating for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a fundamental rating of 2 / 10 to TOI.


Can you provide the valuation status for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a valuation rating of 1 / 10 to ONCOLOGY INSTITUTE INC/THE (TOI). This can be considered as Overvalued.


How profitable is ONCOLOGY INSTITUTE INC/THE (TOI) stock?

ONCOLOGY INSTITUTE INC/THE (TOI) has a profitability rating of 0 / 10.


Can you provide the financial health for TOI stock?

The financial health rating of ONCOLOGY INSTITUTE INC/THE (TOI) is 2 / 10.


Can you provide the expected EPS growth for TOI stock?

The Earnings per Share (EPS) of ONCOLOGY INSTITUTE INC/THE (TOI) is expected to decline by -36.9% in the next year.